Speaker(s): 
Thomas Morland, MD - Geisinger Primary Care. Disclosures include Tempus Labs and United Therapeutics.

Moderator(s): 
Dan Houston, DNP, RN, BC-ADM, Wellness Program - Steele Institute, has nothing to disclose.

Learning Objectives: 
At the conclusion of this session, the participant should be able to: 

• Describe what GLP-1 drugs are, key clinical trials, as well as the effects and downsides of these drugs
• Discuss Geisinger’s T2DM care pathways and guidelines

Disclosure of Relevant Financial Relationships with/without Commercial Interests:
The Planning Committee consisting of Stacy Coolbaugh, MBA, RDN, LDN; Angela Esherick, RDN, LDN, CDCES; Adriene Zook, PharmD, RPH, Dan Huston, DNP, RN, BC-ADM, and Angela Zammit have no identified disclosures. 

CE Committee Member/Content Reviewers Thomas Davis, MD and Andrea DiMattia, EdD; has nothing to disclose.

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 
This presentation/content is HIPPA compliant.